Domestic Delivery For Europe,US,Canada,Australia!
Please note: AASraw does not authorize any resellers.

ACE-031

Rating: Category:

Specification: ACE 031 5MG, ACE031 10MG

AASraw is the professional peptide contract development and manufacturing organization (CDMO) for ACE031, providing customized service tailored to meet specific client needs. Welcome to contact with us for more details!

WARNING: This product is for research use only.

 

Ask for Quick Quote

Product Description

Raw ACE-031 peptide Basic Characters

Product NameACE-031 peptide
CAS No.1621169-52-5
Molecular Formula:C133H227N43O33
Molecular Weight:2956.5 g/mol
Melting Point:NA
Color:White lyophilized powder
Storage Temp:2°C-8°C

 

For the usage and dosage of ACE-031, please refer to the professional guidance provided by the original pharmaceutical company. As a professional manufacturer of ACE-031, AASraw respects and appreciates the research contributions of the original pharmaceutical company and does not provide product usage recommendations.

What is ACE-031?

Some people may loosely call ACE-031 as a “peptide“, but strictly ACE-031 is actually a recombinant fusion protein. It is a fusion of the ActRIIB receptor (a naturally occurring protein in the body) with part of an antibody (Fc region). Belongs to a soluble form of the type IIB activin receptor (ACVR2B), ACE-031 was designed to enhance muscle growth by blocking the activity of myostatin, offering a ray of hope in addressing muscle-wasting diseases such as DMD. With the popularity of peptides in recent years, ACE-031 peptide’s ability to increase muscle growth got attention from bodybuilders and athelets.

What is the mechanism of ACE031?

In the human body, Myostatin is a protein that regulate muscle growth. In the presence of myostatin, muscle development and growth are limited. ACE-031 as myostatin inhibitor, it works by binding to myostatin to prevent its action with muscle cells. This suppression leads to increased muscle mass.

What benefits can you get from ACE-031?

①Muscle Growth

ACE-031 inhibits the action of myostatin lead to increase in muscle growth. This could be beneficial for those who suffering from muscle-wasting disease like cachexia, Duchenne Muscular Dystrophy (DMD) and sarcopenia.

②Improved Muscle Strength

With increased muscle growth, ACE-031 has potential benefits to increase muscle strength and improve physical performance.

③Better Muscle Recovery

There is a potential benefit for ACE-031 to aid in faster muscle recovery from inquiries by encouraging muscle development.

④Improvement in Bone Health

Some studies have suggested that ACE-031 can potentially reduce the risk of fractures by improving bone density.

ACE-031 clinical trial and results

Conducted by Acceleron Pharma, the ACE-031 Clinical trial in 2010 was intended to evaluate the efficacy in increasing muscle mass and improveing physical function in DMD patients. Here are the results:

①Phase I Clinical Trials:

In Phase I clinical trial with healthy volunteers, ACE-031 showed an enhancement in lean muscle mass after several weeks of dose. And it will not significantly change the body fat and other metrics.

②Duchenne Muscular Dystrophy (DMD) Trials:

In the clinical trials on DMD patients, patients use ACE-031 could lead to improved muscle function and a slowing of muscle-wasting disease’s progression.

ACE-031 side effects

Whiles ACE-031 showed potential benefits in muscle mass in early trials, there are some side effects are observed. Specially these side effects:

  • Gum bleeding
  • Nosebleeds
  • Blood vessel changes (related to vascular health)

Particularly the cardiovascular risks, these side effects raised the concerns about long-term safety use, lead to halt of the ACE-031 clinical trials in 2011. Since then the further development of ACE-031 use was discontinued.

ACE-031 stack guide

In bodybuilding world, people often stack compound together to maximize the benefits they wish to get. ACE-031 as a myostatin inhibitor, the role of ACE-031 in the stack is to prevent muscle breakdown and allowing more muscle growth. So obviously, ACE-031 peptides can stack with any muscle-building products. The popular muscle-building products for bodybuilding are:

  • Anabolic steroids:including testosterone, trenbolone or other anabolic steroids
  • Peptides for bodybuilding: including GHRP-6, GHRP-2, CJC-1295, HGH, BPC 157 and Follistatin 344
  • SARM: like MK677

ACE-031 VS. Follistatin 344

To increase muscle mass while reduce the body fat is the goals of most bodybuilders. When people talk about myostatin inhibitors, ACE-031 and Follistatin 344 are the often mentioned by bodybuilders. They both inhibit myostatin but work slightly differently. Let us look deep into them.

Mechanism: Compared to ACE-031 mechanism to acts as a “decoy receptor”, binding to ActRIIB receptor and blocking myostatin directly, Follistatin 344 is a naturally occurring protein in the body that not only inhibits myostatin but also binds to other growth factors.

ACE-031 only focuses on suppression of myostatin to promote muscle growth, will not affect other metrics. While Follistatin 344 has broader pathways to control muscle gain, it is less targeted than ACE-031.

Half-life: Follistatin 344 has shorter half-life than ACE-031. ACE-031 has about 10-15 days half-life

Here is the overview on them:

FeatureACE-031 peptideFollistatin 344
MechanismActs as a “decoy receptor”, to bind to ActRIIB receptor and blocking myostatin directly.Not only inhibit myostatin but also bind to other growth factors
Half-Life10-15 daysShorter, requires more frequent dosing
BenefitsSpecifically target to mystotatin to increase muscle mass without affecting other bodily functions.Broad muscle growth, faster and more significant gains
Availabilityclinical use was discontinued, only available in the underground labResearch purposes only, not approved for therapeutic use
PopularityWell-known but not widely used due to the cost and availabilityOften use by bodybuilder

ACE 031 Peptide Synthesis

ACE-031 is very popular myostatin inhibitor many years ago, but it was less used due to its side effects and high cost. Thanks to peptide synthesis and protein engineering these years, ACE-031 now is available in AASraw as a research peptide for the purpose of study.

Researcher interested in ACE-031 peptide for sale are encouraged to visit AASraw which offer cost-effective ACE-031, buy ACE-031 wholesale will get factory price.

ACE-031 peptide storage

How to store ACE-031 peptide, here is the instruction provided by peptide supplier AASraw.

In order to reduce the degradation of peptide active, you should store ACE-031 peptide in refrigerator at all times after you receive the package, you should store it at a temperature between 2°C and 8°C (36°F and 46°F), but do not freeze. Lyophilized powder peptide can be store at -20 degrees Celsius for long-term usage.

After reconstituted, the solution should be stored at around 4 ℃ but do not freeze.

Where to buy ACE-031 peptide?

For those who pursue a perfect body shape and muscle growth, ACE-031 is an incomparable product to use or stack with other products. ACE-031 is not FDA-approved so now it is sold for research purpose. You can buy it from online peptide supplier or in the bodybuilding forum. Before placing an order, it is better to ask the ACE-031 peptide supplier to send the COA or other testing report to ensure the quality. If you wish to buy high quality ACE-031 peptide, AASraw will be one of the supplier you don’t want to miss.

ACE-031 peptide Testing Report-HNMR

What is HNMR and What does HNMR spectrum tell you? 
H Nuclear Magnetic Resonance (NMR) spectroscopy is an analytical chemistry technique used in quality control
and research for determining the content and purity of a sample as well as its molecular structure.For example,
NMR can quantitatively analyze mixtures containing known compounds.For unknown compounds,NMR can either be used 
to match against spectral libraries or to infer the basic structure directly.Once the basic structure is known,
NMR can be used to determine molecular conformation in solution as well as studying physical properties at the
molecular level such as conformational exchange,phase changes,solubility,and diffusion.

How to buy ACE-031 peptide from AASraw?

❶To contact us by our email inquiry system,or leave your whatsapp number to us,our customer service representative(CSR) will contact with you in 12 hours.

❷To provide us your inquired quantity and address.

❸Our CSR will provide you the quotation, payment term, tracking number, delivery ways and estimated arrival date(ETA).

❹Payment done and the goods will be sent out in 12 hours.

❺Goods received and give comments.

Author of this article:
Dr. Monique Hong graduated from UK Imperial College London Faculty of Medicine

Scientific Journal paper Author:

1.Kenneth M. Attie MD

Department of Medical Research, Acceleron Pharma, Inc., 128 Sidney Street, Cambridge, Massachusetts, 02139 USA.

2.Hugh J. McMillan MD

Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada.

3.Craig Campbell

Pediatric Neurology Children’s Hospital London Health Sciences Centre London ON Canada

4.Florian P. Thomas, MD, PhD

From Hackensack University Medical Center (F.P.T.), Hackensack Meridian School of Medicine, Nutley, NJ.

5.S. Pearsall

Acceleron Pharma, Cambridge, MA, USA

In no way do these doctors or scientists endorse or advocate the purchase, sale, or use of this product for any reason. Aasraw has no affiliation or relationship, implied or otherwise, with these physicians. The purpose of citing them is to acknowledge and commend the exhaustive research and development work done by the scientists working on this substance.

Reference

[1] “Decoy Receptor”. Encyclopedia of Cancer. Springer Berlin Heidelberg. 2012. p. 1070. doi:10.1007/978-3-642-16483-5_6693. ISBN 978-3-642-16482-8.

[2] Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM. “Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.”Muscle Nerve. 2017 Apr;55(4):458-464. doi: 10.1002/mus.25268. Epub 2016 Dec 23. PMID: 27462804

[3] Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, Kumar R, Willins DA, Seehra JS, Sherman ML. “A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.” Muscle Nerve. 2013 Mar;47(3):416-23. doi: 10.1002/mus.23539. Epub 2012 Nov 21. PMID: 23169607

[4] Cadena SM, Tomkinson KN, Monnell TE, Spaits MS, Kumar R, Underwood KW, Pearsall RS, Lachey JL. “Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type.” J Appl Physiol (1985). 2010 Sep;109(3):635-42. doi: 10.1152/japplphysiol.00866.2009. Epub 2010 May 13. PMID: 20466801

[5] Sunada Y. [Myostatin blockade therapy for muscular atrophy]. Brain Nerve. 2011 Nov;63(11):1271-7. PMID: 22068480

[6] Sunada Y. [Anti-myostatin antibody therapy for myopathies]. Rinsho Shinkeigaku. 2011 Nov;51(11):1157-9. doi: 10.5692/clinicalneurol.51.1157. PMID: 22277518

[7] Yang H, Wei XS, Gong J, Du XM, Feng HB, Su C, Gilmore C, Yue C, Yu SB, Li C, Sui HJ. “The relationship between myodural bridge, atrophy and hyperplasia of the suboccipital musculature, and cerebrospinal fluid dynamics.” Sci Rep. 2023 Nov 2;13(1):18882. doi: 10.1038/s41598-023-45820-x. PMID: 37919345

[8] Thevis M, Schänzer W. “Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis – Potential implications for sports drug testing programs.” Rapid Commun Mass Spectrom. 2016 Mar 15;30(5):635-51. doi: 10.1002/rcm.7470. PMID: 26842585

[9] Li C, Yue C, Liu ZC, Gong J, Wei XS, Yang H, Gilmore C, Yu SB, Hack GD, Sui HJ. “The relationship between myodural bridges, hyperplasia of the suboccipital musculature, and intracranial pressure.” PLoS One. 2022 Sep 2;17(9):e0273193. doi: 10.1371/journal.pone.0273193. eCollection 2022. PMID: 36054096

[10] Pearsall, R.S., Davies, M.V., Cannell, M. et al. “Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease.” Sci Rep 9, 11392 (2019). https://doi.org/10.1038/s41598-019-47818-w


Get a Bulk quotation